Bisnorcymserine
Code | Size | Price |
---|
TAR-T26827-5mg | 5mg | £1,010.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T26827-50mg | 50mg | £1,982.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T26827-100mg | 100mg | £2,560.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Bisnorcymserine is a reversible inhibitor of butyrylcholinesterase. The leaving group, bisnoreseroline, interacts in a non-covalent way with Ser(200) and His(440), disrupting the existing interactions within the catalytic triad, and it stacks with Trp(84) at the bottom of the gorge, giving rise to an unprecedented hydrogen-bonding contact.
CAS:
219920-81-7
Formula:
C21H25N3O2
Molecular Weight:
351.45
Purity:
0.98
SMILES:
[H][C@]12NCC[C@@]1(C)c1cc(OC(=O)Nc3ccc(cc3)C(C)C)ccc1N2
References
1. Bartolucci C, Stojan J, Yu QS, Greig NH, Lamba D. Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. Biochem J. 2012 Jun 1;444(2):269-77. doi: 10.1042/BJ20111675. PubMed PMID: 22390827; PubMed Central PMCID: PMC4979005.
2. Kamal MA, Klein P, Yu QS, Tweedie D, Li Y, Holloway HW, Greig NH. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis. 2006 Sep;10(1):43-51. PubMed PMID: 16988481.
3. Macdonald IR, Rockwood K, Martin E, Darvesh S. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? J Alzheimers Dis. 2014;42(2):379-84. doi: 10.3233/JAD-140219. Review. PubMed PMID: 24898642.
4. Ahmad SS, Akhtar S, Jamal QM, Rizvi SM, Kamal MA, Khan MK, Siddiqui MH. Multiple Targets for the Management of Alzheimer's Disease. CNS Neurol Disord Drug Targets. 2016;15(10):1279-1289. PubMed PMID: 27712576.